The U.S. Food and Drug Administration (FDA) has cleared AliveCor's Kardia AI V2 next generation of interpretive artificial intelligence (AI)-based personal electrocardiogram (ECG) algorithms.

The U.S. Food and Drug Administration (FDA) has cleared AliveCor's Kardia AI V2 next generation of interpretive artificial intelligence (AI)-based personal electrocardiogram (ECG) algorithms.

News | Artificial Intelligence | November 24, 2020
FDA Clears First AI-Powered Algorithm Suite for Personal ECG Monitoring
November 24, 2020 — The U.S. Food and Drug Administration (FDA) has cleared AliveCor's next generation of interpretive...
read more
One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session. #AHA2020 #AHA20 #AHA

One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session.

News | Stents | November 24, 2020
Biodegradable Drug Eluting Coronary Stent Noninferior to Xience or Promus Durable Polymer Stents
November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT (...
read more
Leveraging the Right Image and Reporting Platform in Cardiology for Optimal Performance and Outcomes and picking a cardiovascular information system (CVIS).
Case Study | Cardiovascular Information Systems (CVIS) | November 23, 2020
Leveraging the Right Image and Reporting Platform in Cardiology for Optimal Performance and Outcomes
This Frost & Sullivan Executive White Paper explains that digitization is the shift to value-based care and risk-...
read more
Videos | Coronavirus (COVID-19) | November 18, 2020
VIDEO: Lingering Myocardial Involvement After COVID-19 Infection
Aaron Baggish, M.D., director of the cardiovascular performance program, Massachusetts General Hospital. He was on a...
read more
Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. #AHA #AHA20 #AHA2020 #COVID19 #Coronavirus #SARSCoV2

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. 

News | Coronavirus (COVID-19) | November 18, 2020 | Dave Fornell, Editor
COVID-19 Patients With Cardiovascular Disease Have In-hospital Mortality Rates of 25 to 38 Percent
November 18, 2020 — A late-breaking study at the 2020 American Heart Association (AHA) Scientific Sessions showed...
read more
RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm
News | November 18, 2020
Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF
November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial...
read more
Black patient being tested for COVID-19 using a nasal swab PCR test. black adults with COVID-19 were far more likely to be hospitalized than their white counterparts according to data from the AHA COVID-19 Cardiovascular Disease Registry. #AHA #AHA20 #AHA2020 #COVID19 #SARSCoV2

Black patient being tested for COVID-19 using a nasal swab PCR test. Black adults with COVID-19 were far more likely to be hospitalized than their white counterparts according to new data from the AHA COVID-19 Cardiovascular Disease Registry. 

Feature | Coronavirus (COVID-19) | November 18, 2020
COVID-19 Cardiovascular Registry Details Disparities Among Hospitalized Patients
November 18, 2020 -- A new American Heart Association (AHA) collaborative model for COVID-19 (SARS-CoV-2) research,...
read more
Videos | Atrial Fibrillation | November 18, 2020
VIDEO: Screening for Atrial Fibrillation Using Single Lead ECG in the VITAL-AF Trial
Steven Lubitz, M.D., MPH, cardiac electrophysiologist, Massachusetts General Hospital, presented the late-breaking...
read more

The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. 

Feature | Heart Valve Technology | November 17, 2020
TAVR Is Now Dominant Form of Aortic Valve Replacement in the United States
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more...
read more
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
Boston Scientific Pulls Lotus Edge TAVR Valve Off The Market
November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge...
read more
Women’s Heart Attack Research Program (HARP) shows combining OCT and cardiac MRI can detect the underlying cause of heart attack in women who did not have blocked arteries

The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

News | Cardiac Imaging | November 17, 2020
OCT Combined with MRI Can Identify Cause of Unexplained Heart Attacks in Women
November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many women...
read more
Omega-3 fish oil supplements did not help patients after a heart attack in AHA 2020 study. #AHA #AHA20 #AHA2020. Getty Images

Omega-3 fish oil supplements did not help patients after a heart attack. Getty Images

News | Pharmaceuticals | November 17, 2020
Omega-3s Do Not Reduce Cardiac Events in Recent Heart Attack Survivors
November 17, 2020 — A daily dose of omega-3 fatty acids did not reduce the risk of cardiac events, including secondary...
read more
The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
Wearable Heart Monitor Detects Previously Undiagnosed Atrial Fibrillation to Prevent Hospitalizations, Stroke and Death
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study...
read more
Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
Ticagrelor Not Superior to Clopidogrel in Reducing Heart Attacks During PCI
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to...
read more
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
Patients at Risk of AF May Need Extra Monitoring After Heart Surgery
November 16, 2020 — Atrial fibrillation (AF), an irregular heartbeat that can increase the likelihood of stroke, was...
read more
© Copyright Wainscot Media. All Rights Reserved.